-
Jerry Avorn' (born
February 13, 1948) is a
professor of
medicine at
Harvard Medical School and
Chief Emeritus of the
Division of Pharmacoepidemiology...
-
Archived from the
original on 4
January 2013.
Retrieved 1
January 2013.
Avorn J (April 2013). "Approval of a
tuberculosis drug
based on a paradoxical...
- 1136/bmj.b3569. PMC 2749925. PMID 19776103.
Huybrechts KF,
Palmsten K,
Avorn J,
Cohen LS,
Holmes LB,
Franklin JM, et al. (June 2014). "Antidepressant...
- 5-HT2B. Semaglutide,
another weight-loss drug that
gained m**** po****rity
Avorn J. (2004).
Powerful Medicines, pp. 71-84.
Alfred A. Knopf. Nestler, Eric...
-
Track Development Program Priority review (FDA)
Orphan drug Darrow, JJ;
Avorn, J; Kesselheim, AS (27
March 2014). "New FDA breakthrough-drug category—implications...
- PMID 2361170.
Kesselheim AS,
Myers JA,
Solomon DH,
Winkelmayer WC,
Levin R,
Avorn J (2012). "The
prevalence and cost of
unapproved uses of top-selling orphan...
- Los Angeles: SAGE. ISBN 978-1-4522-4031-2. OCLC 899880624.
Kesselheim AS,
Avorn J,
Sarpatwari A (23
August 2016). "The High Cost of
Prescription Drugs in...
- 1, 2024.
Kesselheim AS,
Myers JA,
Solomon DH,
Winkelmayer WC,
Levin R,
Avorn J (February 2012). Alessi-Severini S (ed.). "The
prevalence and cost of...
-
National Archives. 2016-08-15.
Sections 90.7, 90.8.
Retrieved 2020-08-28.
Avorn J.
Powerful Medicines: The Benefits, Risks, and
Costs of
Prescription Drugs...
- needed] One of the
goals of the bill was
streamlining approval, but
Jerry Avorn and
Aaron Kesselheim pointed out that a
third of
medicines are approved...
